Sector News

Heptares, Sosei shuffle leadership as CSO Marshall departs

January 22, 2018
Life sciences

Fiona Marshall, Ph.D., is set to leave Sosei. Marshall has served as CSO of the company since it bought Heptares but is now departing to take on a senior role at another business.

Sosei responded to the resignation of Marshall—who will leave at the end of next month—by giving Malcolm Weir, Ph.D., responsibility for its R&D activities. Weir, like Marshall, joined Sosei through the takeover of British GPCR specialist Heptares. Marshall and Weir co-founded Heptares and, as CSO and CEO, respectively, led it to a $400 million (£287 million) takeover by Sosei.

Since then, Heptares and its team have been integral to Sosei’s plans. Both Marshall and Weir hold EVP positions, with the former taking the CSO title and the latter serving as chief R&D officer. With Marshall departing, Sosei’s R&D activities will continue under Weir’s leadership.

Weir will get support from the newly promoted Tim Tasker, M.D. Tasker, who joined Heptares a year before the 2015 Sosei takeover, is now the Japanese company’s CMO and part of its executive team. The promotion of a doctor with decades of experience running trials at Evotec and GlaxoSmithKline comes at a time when Sosei is preparing to ramp up its clinical development activities.

“[Tasker’s] expertise is crucial to supporting our partnered programs and more importantly to drive our proprietary programs, of which we plan to advance at least six candidates into clinical studies over the next two years, including HTL0018318, our selective muscarinic M1 agonist, which we expect to start a phase 2 trial in patients with dementia with Lewy bodies in Japan during this year,” Sosei CEO Peter Bains said in a statement.

Shares in Sosei traded down 6% following news of Marshall’s departure.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).